Quest Diagnostics Incorporated (DGX) has seen noticeable activity surrounding its stocks. Multiple institutions such as
1832 Asset Management L.P., Waterloo Capital L.P., The Manufacturers Life Insurance Company, TD Asset Management Inc have either purchased or increased their positions in Quest Diagnostics. Conversely, companies like
Crossmark Global Holdings Inc., Stifel Financial Corp., and CIBC Asset Management Inc have trimmed or sold their positions in the company. Despite some losses, Quest Diagnostics' stocks have
bested its rivals on certain days. The company declared a
quarterly cash dividend and displayed an enhanced relative strength, although short of the benchmark. The company is making a mark in digital pathology via the acquisition of PathAI Diagnostics. This move is likely to amplify
AI and Digital Pathology application in cancer diagnosis. Furthermore, the company has revealed the
MelaNodal Predict ™ Test for melanoma risk prediction and added a p-tau217 blood biomarker to their service suite. It has unveiled an
88-Compound Novel Psychoactive Substance Test Panel and decided cooperation with companies like
Instacart and
Fitbit. Despite reimbursement woes, the company is forging ahead with new alliances. Despite occasional underperformance, some suggest the stock is undervalued.
Quest Diagnostics DGX News Analytics from Wed, 30 Aug 2023 07:00:00 GMT to Sun, 09 Jun 2024 15:47:03 GMT -
Rating 4
- Innovation 7
- Information 6
- Rumor 5
